Compare UCL & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCL | CVM |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 30.1M |
| IPO Year | 2019 | 1996 |
| Metric | UCL | CVM |
|---|---|---|
| Price | $0.41 | $1.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 151.6K |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.34 | $0.89 |
| 52 Week High | $2.79 | $10.83 |
| Indicator | UCL | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 29.95 | 58.46 |
| Support Level | $0.34 | $0.95 |
| Resistance Level | $0.99 | $1.80 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 7.73 | 80.33 |
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.